326 related articles for article (PubMed ID: 22685582)
1. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
2. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.
Liu L; Ma Y; Wang RL; Xu WR; Wang SQ; Chou KC
Drug Des Devel Ther; 2013; 7():279-88. PubMed ID: 23630413
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
4. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
Zhang LS; Wang SQ; Xu WR; Wang RL; Wang JF
PLoS One; 2012; 7(10):e48453. PubMed ID: 23119024
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
[TBL] [Abstract][Full Text] [Related]
6. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
7. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations.
Feng XY; Jia WQ; Liu X; Jing Z; Liu YY; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():178-189. PubMed ID: 30557816
[TBL] [Abstract][Full Text] [Related]
11. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
[TBL] [Abstract][Full Text] [Related]
13. A new insight into the treatment of diabetes by means of pan PPAR agonists.
Chandra A; Kaur P; Sahu SK; Mittal A
Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085
[TBL] [Abstract][Full Text] [Related]
14. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
Younk LM; Uhl L; Davis SN
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):753-63. PubMed ID: 21521130
[TBL] [Abstract][Full Text] [Related]
16. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
17.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
19. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
20. The next generation of PPAR drugs: do we have the tools to find them?
Shearer BG; Billin AN
Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
